SlideShare a Scribd company logo
Lack of means, France moves towards
forced collective immunity
A. France and Europe seen from Asia - We are at
war, and the Asian examples show us the way
forward!
This section is produced with discussions with Dr Bachir Athmani in Paris and Mathieu
Bouquet in China.
“Put down the masks” and stop half-measures: we must adopt the recipes that work!
1. Wearing a mask (if possible generalized!)
This tactic has proven itself: there are countries that use it and that win ... and others!
If our industry is not able to supply this type of product (which shows our extreme
dependence on China, already illustrated by the cost hunt in the pharmaceutical industry),
we must turn to l factory in the world, which currently produces 100 million masks ... per day!
(against a capacity of less than 10 million per ... week in France). Even if China produces of
course with varying levels of quality.
The masks (FFP2, surgical) must initially be reserved for healthcare professionals (around 2
million units per day) as well as for people in repeated contact with the public (Ehpad, police,
cashiers, etc.).
2. Massive screening
This is the key to the Korean strategy to detect cases and isolate them immediately.
Note the figure of 500,000 tests per week in Germany, compared with less than 50,000 per
week for France.
The development of this type of reagent by our laboratories (human or even veterinary
biology) is not, according to some specialists, a very complex element. Chinese, Koreans
and even Vietnamese did it urgently, without having a month of preparation before the arrival
of the epidemic on their territory.
3. Massive disinfection of public spaces
This is the case in China and South Korea in particular. Note the use of spray robots in these
two countries.
4. Identification and management of positive cases and contact
cases
This is an essential point.
In China and most Asian countries, a ​Covid patient is immediately isolated in hospital or
in a quarantine center​. This measure was initiated in Hubei, after the authorities became
aware of the very large number of intra-family contaminations (some families have been
decimated).
In France, a patient with little symptoms returns to his family, which creates a great risk of
family contamination.
Likewise, in China if a ​contact person​ is identified, they are ​under quarantine​. Quarantine
is now done in dedicated centers, and much more rarely at home.
If a suspect case is identified, isolation of the entire residence (China, Vietnam, etc.) until the
doubt is resolved. If the case is positive, the patient is isolated in hospital, and the
confinement of the residence is maintained for 14 days, with temperature monitoring and
possibly biological tests.
5. War effort: DIY or deployment in order?
Some hairy people spent months in the trenches. We have to spend 4 weeks (+/- 2) at
home.
All industry​ that can be mobilized must ​provide solutions​ for the development of the basic
elements of the fight against the virus (protective gear, care materials, etc.).
The lack of beds in public hospitals (eg in Paris: the 1,000 intensive care beds are occupied
or about to be occupied) can be compensated by the participation of the private sector.
Reduction of summer holidays ​for schoolchildren, university students and their parents
(solution preferred by China and Vietnam, where classes have not yet resumed).
Our health system must reposition itself in an emergency, when it is above all risk-oriented:
● acute​ (“White Plan”): mechanical (trauma) or chemical (see recently in the West) or
thermal or even nuclear type
● localized ​(type of attack or major accident) and not throughout the country.
● non-progressive, ​whereas we have to face an epidemic period of around 2 months
days (Wuhan case) with strict containment measures.
This may explain the difficulties encountered by our managers in adapting existing means.
B. France - We are rather following an Italian
trajectory - D11 containment
1. Incidence: +3,922 new confirmed cases (2,933 yesterday)
We remain in the epidemic growth phase, the number of new cases does not seem stable
over the last 4 days.
Note that general practitioners and the 15th have identified more than 40,000 positive cases
since the start of the epidemic, without confirmation by biological tests.
2. Prevalence: 22.5k in observation (20k yesterday)
On this basis alone, ​the doubling time seems to be getting longer (more than 6 days,
compared to 5 yesterday). But the figure of 22,500 does not take into account the
biologically unconfirmed cases mentioned in the previous paragraph.
If France continues to follow the Italian model, the peak could end around mid-April.
3. Trend (comparison with Italy)
To date, France's trajectory remains relatively close to that of Italy, with all the necessary
precautions for this comparison, in particular with regard to the testing strategy adopted by
each country.
4. Health system: analysis of current capacities and flows
4.1. Figures
Deaths: ​1,696, or 6% of cases identified by biological tests (but much lower if we took into
account all people carrying the virus in France)
Severe cases (resuscitation): ​3,375, or 14% of cases identified biologically
4.2. Testimony of a colleague in the Grand Est to the emergency
“I have never had this experience: we usually have 150 visits to the emergency room and at
most we intubate once a day. Today, we have received only 70 patients but we had to
intubate 10 ".
4.3. Our system is still capable of absorbing the wave ...
... but probably more for a very long time. While Italy has already seen its capacities
overwhelmed by the epidemic.
Graph: proportion of severe cases among identified cases
Graphiques : comparaison par pays des cas graves et décès
Note the dynamics of mortality rates (an indicator that is doubtful but its dynamic is a good
indicator) on the rise in France, and which only reflects the difficulties encountered more and
more frequently by carers, in a similar way to what is happening in Spain.
NB: precautions to take on mortality figures
In France, the mortality figures provided are probably largely underestimated compared to
reality, since only the figures for hospital mortality are included and consequently they do not
include figures outside the hospital (Ehpad, deaths without biological tests carried out, etc. .).
5. Territorial distribution
NB: the figures for March 26 in the evening were not communicated by region, the map and
the table below show the data available on March 25 in the evening.
5.1. Cartography
5.2. Evolution by region
C. World impact: an exponential dynamic
Thanks to Stéphane, a companion from the start, for his participation.
1. Incidence: 63k new cases diagnosed (46k yesterday, 44k
the day before)
2. Global geographic vision
There are currently the equivalent of 15 Wuhan type homes around the world, including ten
exploded in Europe and which can be joined!
The United States and Spain remain in an exponential phase.
3. Continent / country geographic analysis
3.1. Par continent
3.2. By country
There is a high risk of health catastrophe in the United States, where the best technology will
not be able to cope with a massive influx of patients at risk, in particular due to
co-morbidities. Obesity, with its pathological consequences, affects more than a third of
American adults.
Table: evolution by country
Zagury day 60 english content
D. Prevalence worldwide - In a few days, the
United States reaches a number of cumulative
cases greater than that of China in 2 months!
The doubling time in the United States is currently 3 days.
1. Time vision (chronological)
At the current rate, doubling of cases worldwide every 5 days (stable).
Figures to be taken with caution given the disparity of testing strategies: the epidemic can
spread without it being reflected in the official figures, if the patients are not subject to
biological screening and a count official.
2. Spatial vision
Geographical location of countries with more than 10,000 active cases (top 8):
● USA 82k
● Italy 62k
● Spain 46k
● Germany 38k
● France 22.5k
● Iran 16.7k
● Switzerland 11.5k (high density of imported cases)
● United Kingdom 11k
Chart: distribution by continent
Thanks to Mathieu Bouquet, partner from the start, for his precious help.
Keep in mind the “3M reflex” (Hands-Masks-Meter) to protect
yourself… but above all to protect the most vulnerable.
Trust and solidarity for this collective fight
Dr Guillaume ZAGURY
Specialist in International Public Health
Consultant in “Health Innovations” ​
HEC
In China since 2000.
● “All success is collective”, thanks to:
○ the whole “Back Up” team (Mathieu Bousquet, Carole Gabay, Flavien, Marie, Laetitia,
Anne-Sophie, ...), without whom this project would not have been possible.
○ all the “Medical” team (Dr Bachir Athmani, Dr Ibrahim Souare , Dr Taieb, Dr Viateur
...) who allow this project to exist,
○ all historical financial sponsors (Jerome, Benjamin Denis & B Square, Benoit
Rossignol, Arnault Bricout) who work for “Citizen Actions”
● If you feel like a patron or of partners to finance IT development, don't hesitate to contact me
(guillaume@covidminute.com).
● Also, even if part of the team is based in Shanghai, do not hesitate to come and join us,
because there is no shortage of work :-)

More Related Content

Similar to Zagury day 60 english content

18 jun20 ILC Global Alliance webinar presentation
18 jun20 ILC Global Alliance webinar presentation18 jun20 ILC Global Alliance webinar presentation
18 jun20 ILC Global Alliance webinar presentation
ILC- UK
 
Jebs covid 19 pandemic and the management strategy for business and economy ...
Jebs covid  19 pandemic and the management strategy for business and economy ...Jebs covid  19 pandemic and the management strategy for business and economy ...
Jebs covid 19 pandemic and the management strategy for business and economy ...
M. Luisetto Pharm.D.Spec. Pharmacology
 
Jebs covid 19 pandemic and the management strategy for business and economy l...
Jebs covid 19 pandemic and the management strategy for business and economy l...Jebs covid 19 pandemic and the management strategy for business and economy l...
Jebs covid 19 pandemic and the management strategy for business and economy l...
M. Luisetto Pharm.D.Spec. Pharmacology
 
Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...
Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...
Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...
Shivam Parmar
 
Covid 19-facts-and-insights-april-3-v2-2
Covid 19-facts-and-insights-april-3-v2-2Covid 19-facts-and-insights-april-3-v2-2
Covid 19-facts-and-insights-april-3-v2-2
FlavioAntonelli1
 
Covid 19-facts-and-insights-april-3-v2-3
Covid 19-facts-and-insights-april-3-v2-3Covid 19-facts-and-insights-april-3-v2-3
Covid 19-facts-and-insights-april-3-v2-3
FlavioAntonelli1
 
Evidance based managment of COVID-19 patients
Evidance based managment of COVID-19 patientsEvidance based managment of COVID-19 patients
Evidance based managment of COVID-19 patients
Saren Azer
 
Resilience strategy in emergency medicine during the Covid-19 pandemic in Paris
Resilience strategy in emergency medicine during the Covid-19 pandemic in ParisResilience strategy in emergency medicine during the Covid-19 pandemic in Paris
Resilience strategy in emergency medicine during the Covid-19 pandemic in Paris
DrMINKAHillary
 
OVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSIS
OVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSISOVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSIS
OVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSIS
Global Risk Forum GRFDavos
 
Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...
Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...
Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...
Biocomplexity Institute of Virginia Tech
 
Lessons from Ebola: Preventing the Next Epidemic
Lessons from Ebola: Preventing the Next Epidemic Lessons from Ebola: Preventing the Next Epidemic
Lessons from Ebola: Preventing the Next Epidemic
Abioye Peju
 
Innovative twinning programme in prison setting
Innovative twinning programme in prison settingInnovative twinning programme in prison setting
Innovative twinning programme in prison setting
Vih.org
 
Conference Paper WHO version geneva city 2006
Conference Paper  WHO version geneva city 2006Conference Paper  WHO version geneva city 2006
Conference Paper WHO version geneva city 2006
Hans Salas Maronsky
 
Mc kinsey covid-19-facts-and-insights-march-25-v3
Mc kinsey covid-19-facts-and-insights-march-25-v3Mc kinsey covid-19-facts-and-insights-march-25-v3
Mc kinsey covid-19-facts-and-insights-march-25-v3
Queiroz Galvão Óleo e Gás S.A.
 
Zagury 27.02.2020 Covid-19 / Innovation / Daily report / Géopathologie
Zagury 27.02.2020 Covid-19 / Innovation / Daily report / GéopathologieZagury 27.02.2020 Covid-19 / Innovation / Daily report / Géopathologie
Zagury 27.02.2020 Covid-19 / Innovation / Daily report / Géopathologie
GuillaumeZagury
 
Compare and Contrast Healthcare delivery in France and the UK
Compare and Contrast Healthcare delivery in France and the UKCompare and Contrast Healthcare delivery in France and the UK
Compare and Contrast Healthcare delivery in France and the UK
meducationdotnet
 
Yaws
YawsYaws
Control and Eradication of Animal diseases.pptx
Control and Eradication of Animal diseases.pptxControl and Eradication of Animal diseases.pptx
Control and Eradication of Animal diseases.pptx
Bhoj Raj Singh
 
EMERGING and RE-EMERGING DISEASES.pptx
EMERGING and RE-EMERGING DISEASES.pptxEMERGING and RE-EMERGING DISEASES.pptx
EMERGING and RE-EMERGING DISEASES.pptx
Allen Rojer
 
Destitute Roma & access to healthcare
Destitute Roma & access to healthcareDestitute Roma & access to healthcare
Destitute Roma & access to healthcare
European Economic and Social Committee - SOC Section
 

Similar to Zagury day 60 english content (20)

18 jun20 ILC Global Alliance webinar presentation
18 jun20 ILC Global Alliance webinar presentation18 jun20 ILC Global Alliance webinar presentation
18 jun20 ILC Global Alliance webinar presentation
 
Jebs covid 19 pandemic and the management strategy for business and economy ...
Jebs covid  19 pandemic and the management strategy for business and economy ...Jebs covid  19 pandemic and the management strategy for business and economy ...
Jebs covid 19 pandemic and the management strategy for business and economy ...
 
Jebs covid 19 pandemic and the management strategy for business and economy l...
Jebs covid 19 pandemic and the management strategy for business and economy l...Jebs covid 19 pandemic and the management strategy for business and economy l...
Jebs covid 19 pandemic and the management strategy for business and economy l...
 
Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...
Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...
Covid-19 Pandemic, where are we now? Latest update on Covid-19 Second Wave 20...
 
Covid 19-facts-and-insights-april-3-v2-2
Covid 19-facts-and-insights-april-3-v2-2Covid 19-facts-and-insights-april-3-v2-2
Covid 19-facts-and-insights-april-3-v2-2
 
Covid 19-facts-and-insights-april-3-v2-3
Covid 19-facts-and-insights-april-3-v2-3Covid 19-facts-and-insights-april-3-v2-3
Covid 19-facts-and-insights-april-3-v2-3
 
Evidance based managment of COVID-19 patients
Evidance based managment of COVID-19 patientsEvidance based managment of COVID-19 patients
Evidance based managment of COVID-19 patients
 
Resilience strategy in emergency medicine during the Covid-19 pandemic in Paris
Resilience strategy in emergency medicine during the Covid-19 pandemic in ParisResilience strategy in emergency medicine during the Covid-19 pandemic in Paris
Resilience strategy in emergency medicine during the Covid-19 pandemic in Paris
 
OVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSIS
OVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSISOVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSIS
OVERVIEW ON HUMAN VACCINES AGAINST LEPTOSPIROSIS
 
Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...
Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...
Computational Epidemiology tutorial featured at ACM Knowledge Discovery and D...
 
Lessons from Ebola: Preventing the Next Epidemic
Lessons from Ebola: Preventing the Next Epidemic Lessons from Ebola: Preventing the Next Epidemic
Lessons from Ebola: Preventing the Next Epidemic
 
Innovative twinning programme in prison setting
Innovative twinning programme in prison settingInnovative twinning programme in prison setting
Innovative twinning programme in prison setting
 
Conference Paper WHO version geneva city 2006
Conference Paper  WHO version geneva city 2006Conference Paper  WHO version geneva city 2006
Conference Paper WHO version geneva city 2006
 
Mc kinsey covid-19-facts-and-insights-march-25-v3
Mc kinsey covid-19-facts-and-insights-march-25-v3Mc kinsey covid-19-facts-and-insights-march-25-v3
Mc kinsey covid-19-facts-and-insights-march-25-v3
 
Zagury 27.02.2020 Covid-19 / Innovation / Daily report / Géopathologie
Zagury 27.02.2020 Covid-19 / Innovation / Daily report / GéopathologieZagury 27.02.2020 Covid-19 / Innovation / Daily report / Géopathologie
Zagury 27.02.2020 Covid-19 / Innovation / Daily report / Géopathologie
 
Compare and Contrast Healthcare delivery in France and the UK
Compare and Contrast Healthcare delivery in France and the UKCompare and Contrast Healthcare delivery in France and the UK
Compare and Contrast Healthcare delivery in France and the UK
 
Yaws
YawsYaws
Yaws
 
Control and Eradication of Animal diseases.pptx
Control and Eradication of Animal diseases.pptxControl and Eradication of Animal diseases.pptx
Control and Eradication of Animal diseases.pptx
 
EMERGING and RE-EMERGING DISEASES.pptx
EMERGING and RE-EMERGING DISEASES.pptxEMERGING and RE-EMERGING DISEASES.pptx
EMERGING and RE-EMERGING DISEASES.pptx
 
Destitute Roma & access to healthcare
Destitute Roma & access to healthcareDestitute Roma & access to healthcare
Destitute Roma & access to healthcare
 

More from GuillaumeZagury

Zagury 14.03.2020
Zagury 14.03.2020Zagury 14.03.2020
Zagury 14.03.2020
GuillaumeZagury
 
Zagury 13.03.2020
Zagury 13.03.2020Zagury 13.03.2020
Zagury 13.03.2020
GuillaumeZagury
 
Zagury 12.03.2020 fr
Zagury 12.03.2020 frZagury 12.03.2020 fr
Zagury 12.03.2020 fr
GuillaumeZagury
 
Zagury 11.03.2020
Zagury 11.03.2020Zagury 11.03.2020
Zagury 11.03.2020
GuillaumeZagury
 
Zagury 10.03.2020
Zagury 10.03.2020Zagury 10.03.2020
Zagury 10.03.2020
GuillaumeZagury
 
Zagury 09.03.2020
Zagury 09.03.2020Zagury 09.03.2020
Zagury 09.03.2020
GuillaumeZagury
 
Zagury 08.03.2020
Zagury 08.03.2020Zagury 08.03.2020
Zagury 08.03.2020
GuillaumeZagury
 
Zagury 07.03.2020
Zagury 07.03.2020Zagury 07.03.2020
Zagury 07.03.2020
GuillaumeZagury
 
Zagury 06.03.2020
Zagury 06.03.2020Zagury 06.03.2020
Zagury 06.03.2020
GuillaumeZagury
 
Zagury 04.03.2020
Zagury 04.03.2020Zagury 04.03.2020
Zagury 04.03.2020
GuillaumeZagury
 
Zagury 03.03.2020
Zagury 03.03.2020Zagury 03.03.2020
Zagury 03.03.2020
GuillaumeZagury
 
Zagury 01.03.2020 Covid19 / Géopathologie
Zagury 01.03.2020 Covid19 / GéopathologieZagury 01.03.2020 Covid19 / Géopathologie
Zagury 01.03.2020 Covid19 / Géopathologie
GuillaumeZagury
 
Zagury 29.02.2020 / Covid19 / Géopathologie / Daily report
Zagury 29.02.2020 / Covid19 / Géopathologie / Daily reportZagury 29.02.2020 / Covid19 / Géopathologie / Daily report
Zagury 29.02.2020 / Covid19 / Géopathologie / Daily report
GuillaumeZagury
 
Zagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily report
Zagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily reportZagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily report
Zagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily report
GuillaumeZagury
 
Zagury 26.02.2020 Covid-2019 / Innovation / Géopathologie
Zagury 26.02.2020 Covid-2019 / Innovation / GéopathologieZagury 26.02.2020 Covid-2019 / Innovation / Géopathologie
Zagury 26.02.2020 Covid-2019 / Innovation / Géopathologie
GuillaumeZagury
 
Zagury 25.02.2020 Covid-19 / Innovation / geopolitique
Zagury 25.02.2020 Covid-19 / Innovation / geopolitiqueZagury 25.02.2020 Covid-19 / Innovation / geopolitique
Zagury 25.02.2020 Covid-19 / Innovation / geopolitique
GuillaumeZagury
 
Zagury 24.02.2020 Covid-19 / Innovation
Zagury 24.02.2020 Covid-19 / InnovationZagury 24.02.2020 Covid-19 / Innovation
Zagury 24.02.2020 Covid-19 / Innovation
GuillaumeZagury
 
Zagury 22.02.2020 Covid - 19 / Innovations / Daily report
Zagury 22.02.2020 Covid - 19 / Innovations / Daily reportZagury 22.02.2020 Covid - 19 / Innovations / Daily report
Zagury 22.02.2020 Covid - 19 / Innovations / Daily report
GuillaumeZagury
 
Zagury 21.02.2020 Covid-19
Zagury 21.02.2020 Covid-19Zagury 21.02.2020 Covid-19
Zagury 21.02.2020 Covid-19
GuillaumeZagury
 
Zagury 20.02.2020 Covid-19
Zagury 20.02.2020 Covid-19Zagury 20.02.2020 Covid-19
Zagury 20.02.2020 Covid-19
GuillaumeZagury
 

More from GuillaumeZagury (20)

Zagury 14.03.2020
Zagury 14.03.2020Zagury 14.03.2020
Zagury 14.03.2020
 
Zagury 13.03.2020
Zagury 13.03.2020Zagury 13.03.2020
Zagury 13.03.2020
 
Zagury 12.03.2020 fr
Zagury 12.03.2020 frZagury 12.03.2020 fr
Zagury 12.03.2020 fr
 
Zagury 11.03.2020
Zagury 11.03.2020Zagury 11.03.2020
Zagury 11.03.2020
 
Zagury 10.03.2020
Zagury 10.03.2020Zagury 10.03.2020
Zagury 10.03.2020
 
Zagury 09.03.2020
Zagury 09.03.2020Zagury 09.03.2020
Zagury 09.03.2020
 
Zagury 08.03.2020
Zagury 08.03.2020Zagury 08.03.2020
Zagury 08.03.2020
 
Zagury 07.03.2020
Zagury 07.03.2020Zagury 07.03.2020
Zagury 07.03.2020
 
Zagury 06.03.2020
Zagury 06.03.2020Zagury 06.03.2020
Zagury 06.03.2020
 
Zagury 04.03.2020
Zagury 04.03.2020Zagury 04.03.2020
Zagury 04.03.2020
 
Zagury 03.03.2020
Zagury 03.03.2020Zagury 03.03.2020
Zagury 03.03.2020
 
Zagury 01.03.2020 Covid19 / Géopathologie
Zagury 01.03.2020 Covid19 / GéopathologieZagury 01.03.2020 Covid19 / Géopathologie
Zagury 01.03.2020 Covid19 / Géopathologie
 
Zagury 29.02.2020 / Covid19 / Géopathologie / Daily report
Zagury 29.02.2020 / Covid19 / Géopathologie / Daily reportZagury 29.02.2020 / Covid19 / Géopathologie / Daily report
Zagury 29.02.2020 / Covid19 / Géopathologie / Daily report
 
Zagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily report
Zagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily reportZagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily report
Zagury 28.02.2020 Covid19 - Géopathologie / Innovation / Daily report
 
Zagury 26.02.2020 Covid-2019 / Innovation / Géopathologie
Zagury 26.02.2020 Covid-2019 / Innovation / GéopathologieZagury 26.02.2020 Covid-2019 / Innovation / Géopathologie
Zagury 26.02.2020 Covid-2019 / Innovation / Géopathologie
 
Zagury 25.02.2020 Covid-19 / Innovation / geopolitique
Zagury 25.02.2020 Covid-19 / Innovation / geopolitiqueZagury 25.02.2020 Covid-19 / Innovation / geopolitique
Zagury 25.02.2020 Covid-19 / Innovation / geopolitique
 
Zagury 24.02.2020 Covid-19 / Innovation
Zagury 24.02.2020 Covid-19 / InnovationZagury 24.02.2020 Covid-19 / Innovation
Zagury 24.02.2020 Covid-19 / Innovation
 
Zagury 22.02.2020 Covid - 19 / Innovations / Daily report
Zagury 22.02.2020 Covid - 19 / Innovations / Daily reportZagury 22.02.2020 Covid - 19 / Innovations / Daily report
Zagury 22.02.2020 Covid - 19 / Innovations / Daily report
 
Zagury 21.02.2020 Covid-19
Zagury 21.02.2020 Covid-19Zagury 21.02.2020 Covid-19
Zagury 21.02.2020 Covid-19
 
Zagury 20.02.2020 Covid-19
Zagury 20.02.2020 Covid-19Zagury 20.02.2020 Covid-19
Zagury 20.02.2020 Covid-19
 

Recently uploaded

Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
NephroTube - Dr.Gawad
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
drebrahiim
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
Aloy Okechukwu Ugwu
 
anthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology depanthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology dep
sapnasirswal
 
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdfHeart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
MedicoseAcademics
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Trustlife
 
JULY 2024 Oncology Cartoons by Dr Kanhu Charan Patro
JULY 2024 Oncology Cartoons by Dr Kanhu Charan PatroJULY 2024 Oncology Cartoons by Dr Kanhu Charan Patro
JULY 2024 Oncology Cartoons by Dr Kanhu Charan Patro
Kanhu Charan
 
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptxProstatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
AmandaChou9
 
medical law and ethics presentation .ppt
medical law and ethics presentation .pptmedical law and ethics presentation .ppt
medical law and ethics presentation .ppt
PseudoPocket
 
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptxHow to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
AmandaChou9
 
symblephoron types etiology management.pptx
symblephoron types etiology management.pptxsymblephoron types etiology management.pptx
symblephoron types etiology management.pptx
mohammadsumairah
 
Text Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT NursingText Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT Nursing
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 
Approach to Head Injuiry, Intracranial Pressure Measurement and Management.pptx
Approach to Head Injuiry, Intracranial Pressure Measurement and Management.pptxApproach to Head Injuiry, Intracranial Pressure Measurement and Management.pptx
Approach to Head Injuiry, Intracranial Pressure Measurement and Management.pptx
Bipul Thakur
 
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptxPULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
neeti70
 
Text Book of Critical Care Nursing ICU NURSING
Text Book of Critical Care Nursing  ICU NURSINGText Book of Critical Care Nursing  ICU NURSING
Text Book of Critical Care Nursing ICU NURSING
BP KOIRALA INSTITUTE OF HELATH SCIENCS,, NEPAL
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
Bright Chipili
 
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
DRPREETHIJAMESP
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
Mithilesh Chaurasia
 
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
semualkaira
 
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
PVI, PeerView Institute for Medical Education
 

Recently uploaded (20)

Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
Hemodialysis: Chapter 9, Arteriovenous Fistula and Graft: Basics, Creation, U...
 
Drug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptxDrug Repurposing for Parasitic Diseases.pptx
Drug Repurposing for Parasitic Diseases.pptx
 
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptxPICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
PICTURE TEST IN OBSTETRICS AND GYNAECOLOGY-Aloy Okechukwu Ugwu.pptx
 
anthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology depanthelmintic-drugs.pptx pharmacology dep
anthelmintic-drugs.pptx pharmacology dep
 
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdfHeart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
Heart Valves and Heart Sounds -Congenital & valvular heart disease.pdf
 
Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...Article - Design and evaluation of novel inhibitors for the treatment of clea...
Article - Design and evaluation of novel inhibitors for the treatment of clea...
 
JULY 2024 Oncology Cartoons by Dr Kanhu Charan Patro
JULY 2024 Oncology Cartoons by Dr Kanhu Charan PatroJULY 2024 Oncology Cartoons by Dr Kanhu Charan Patro
JULY 2024 Oncology Cartoons by Dr Kanhu Charan Patro
 
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptxProstatitis Severity- How to Determine if You Have Mild Symptoms.pptx
Prostatitis Severity- How to Determine if You Have Mild Symptoms.pptx
 
medical law and ethics presentation .ppt
medical law and ethics presentation .pptmedical law and ethics presentation .ppt
medical law and ethics presentation .ppt
 
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptxHow to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
How to Relieve Prostate Congestion- Here are some Effective Strategies.pptx
 
symblephoron types etiology management.pptx
symblephoron types etiology management.pptxsymblephoron types etiology management.pptx
symblephoron types etiology management.pptx
 
Text Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT NursingText Book of Operation Theater Nursing OT Nursing
Text Book of Operation Theater Nursing OT Nursing
 
Approach to Head Injuiry, Intracranial Pressure Measurement and Management.pptx
Approach to Head Injuiry, Intracranial Pressure Measurement and Management.pptxApproach to Head Injuiry, Intracranial Pressure Measurement and Management.pptx
Approach to Head Injuiry, Intracranial Pressure Measurement and Management.pptx
 
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptxPULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
PULMONARY EMBOLISM AND ITS MANAGEMENT.pptx
 
Text Book of Critical Care Nursing ICU NURSING
Text Book of Critical Care Nursing  ICU NURSINGText Book of Critical Care Nursing  ICU NURSING
Text Book of Critical Care Nursing ICU NURSING
 
THE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptxTHE MANAGEMENT OF PROSTATE CANCER . pptx
THE MANAGEMENT OF PROSTATE CANCER . pptx
 
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
THE REVIEW OF THE ENCYCLOPEDIA OF PURE MATERIA MEDICA.BHMS.MATERIA MEDICA.HOM...
 
2nd week of Human development .embryology
2nd week of Human development .embryology2nd week of Human development .embryology
2nd week of Human development .embryology
 
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
Dr Charles James de Vis, M.R.C.S., L.S.A. England, Surgeon to the Charters To...
 
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
Stepping Forward to Transform MCL Management: Guidance on the Selection and U...
 

Zagury day 60 english content

  • 1. Lack of means, France moves towards forced collective immunity A. France and Europe seen from Asia - We are at war, and the Asian examples show us the way forward! This section is produced with discussions with Dr Bachir Athmani in Paris and Mathieu Bouquet in China. “Put down the masks” and stop half-measures: we must adopt the recipes that work!
  • 2. 1. Wearing a mask (if possible generalized!) This tactic has proven itself: there are countries that use it and that win ... and others! If our industry is not able to supply this type of product (which shows our extreme dependence on China, already illustrated by the cost hunt in the pharmaceutical industry), we must turn to l factory in the world, which currently produces 100 million masks ... per day! (against a capacity of less than 10 million per ... week in France). Even if China produces of course with varying levels of quality. The masks (FFP2, surgical) must initially be reserved for healthcare professionals (around 2 million units per day) as well as for people in repeated contact with the public (Ehpad, police, cashiers, etc.). 2. Massive screening This is the key to the Korean strategy to detect cases and isolate them immediately. Note the figure of 500,000 tests per week in Germany, compared with less than 50,000 per week for France.
  • 3. The development of this type of reagent by our laboratories (human or even veterinary biology) is not, according to some specialists, a very complex element. Chinese, Koreans and even Vietnamese did it urgently, without having a month of preparation before the arrival of the epidemic on their territory. 3. Massive disinfection of public spaces This is the case in China and South Korea in particular. Note the use of spray robots in these two countries. 4. Identification and management of positive cases and contact cases This is an essential point. In China and most Asian countries, a ​Covid patient is immediately isolated in hospital or in a quarantine center​. This measure was initiated in Hubei, after the authorities became aware of the very large number of intra-family contaminations (some families have been decimated). In France, a patient with little symptoms returns to his family, which creates a great risk of family contamination. Likewise, in China if a ​contact person​ is identified, they are ​under quarantine​. Quarantine is now done in dedicated centers, and much more rarely at home. If a suspect case is identified, isolation of the entire residence (China, Vietnam, etc.) until the doubt is resolved. If the case is positive, the patient is isolated in hospital, and the confinement of the residence is maintained for 14 days, with temperature monitoring and possibly biological tests. 5. War effort: DIY or deployment in order? Some hairy people spent months in the trenches. We have to spend 4 weeks (+/- 2) at home. All industry​ that can be mobilized must ​provide solutions​ for the development of the basic elements of the fight against the virus (protective gear, care materials, etc.). The lack of beds in public hospitals (eg in Paris: the 1,000 intensive care beds are occupied or about to be occupied) can be compensated by the participation of the private sector.
  • 4. Reduction of summer holidays ​for schoolchildren, university students and their parents (solution preferred by China and Vietnam, where classes have not yet resumed). Our health system must reposition itself in an emergency, when it is above all risk-oriented: ● acute​ (“White Plan”): mechanical (trauma) or chemical (see recently in the West) or thermal or even nuclear type ● localized ​(type of attack or major accident) and not throughout the country. ● non-progressive, ​whereas we have to face an epidemic period of around 2 months days (Wuhan case) with strict containment measures. This may explain the difficulties encountered by our managers in adapting existing means. B. France - We are rather following an Italian trajectory - D11 containment 1. Incidence: +3,922 new confirmed cases (2,933 yesterday) We remain in the epidemic growth phase, the number of new cases does not seem stable over the last 4 days. Note that general practitioners and the 15th have identified more than 40,000 positive cases since the start of the epidemic, without confirmation by biological tests. 2. Prevalence: 22.5k in observation (20k yesterday) On this basis alone, ​the doubling time seems to be getting longer (more than 6 days, compared to 5 yesterday). But the figure of 22,500 does not take into account the biologically unconfirmed cases mentioned in the previous paragraph. If France continues to follow the Italian model, the peak could end around mid-April. 3. Trend (comparison with Italy) To date, France's trajectory remains relatively close to that of Italy, with all the necessary precautions for this comparison, in particular with regard to the testing strategy adopted by each country.
  • 5. 4. Health system: analysis of current capacities and flows 4.1. Figures Deaths: ​1,696, or 6% of cases identified by biological tests (but much lower if we took into account all people carrying the virus in France) Severe cases (resuscitation): ​3,375, or 14% of cases identified biologically 4.2. Testimony of a colleague in the Grand Est to the emergency “I have never had this experience: we usually have 150 visits to the emergency room and at most we intubate once a day. Today, we have received only 70 patients but we had to intubate 10 ". 4.3. Our system is still capable of absorbing the wave ...
  • 6. ... but probably more for a very long time. While Italy has already seen its capacities overwhelmed by the epidemic. Graph: proportion of severe cases among identified cases Graphiques : comparaison par pays des cas graves et décès Note the dynamics of mortality rates (an indicator that is doubtful but its dynamic is a good indicator) on the rise in France, and which only reflects the difficulties encountered more and more frequently by carers, in a similar way to what is happening in Spain.
  • 7. NB: precautions to take on mortality figures In France, the mortality figures provided are probably largely underestimated compared to reality, since only the figures for hospital mortality are included and consequently they do not include figures outside the hospital (Ehpad, deaths without biological tests carried out, etc. .). 5. Territorial distribution NB: the figures for March 26 in the evening were not communicated by region, the map and the table below show the data available on March 25 in the evening.
  • 9. 5.2. Evolution by region C. World impact: an exponential dynamic Thanks to Stéphane, a companion from the start, for his participation. 1. Incidence: 63k new cases diagnosed (46k yesterday, 44k the day before) 2. Global geographic vision There are currently the equivalent of 15 Wuhan type homes around the world, including ten exploded in Europe and which can be joined!
  • 10. The United States and Spain remain in an exponential phase. 3. Continent / country geographic analysis 3.1. Par continent
  • 11. 3.2. By country There is a high risk of health catastrophe in the United States, where the best technology will not be able to cope with a massive influx of patients at risk, in particular due to co-morbidities. Obesity, with its pathological consequences, affects more than a third of American adults. Table: evolution by country
  • 13. D. Prevalence worldwide - In a few days, the United States reaches a number of cumulative cases greater than that of China in 2 months! The doubling time in the United States is currently 3 days. 1. Time vision (chronological) At the current rate, doubling of cases worldwide every 5 days (stable). Figures to be taken with caution given the disparity of testing strategies: the epidemic can spread without it being reflected in the official figures, if the patients are not subject to biological screening and a count official. 2. Spatial vision Geographical location of countries with more than 10,000 active cases (top 8): ● USA 82k ● Italy 62k ● Spain 46k ● Germany 38k
  • 14. ● France 22.5k ● Iran 16.7k ● Switzerland 11.5k (high density of imported cases) ● United Kingdom 11k Chart: distribution by continent
  • 15. Thanks to Mathieu Bouquet, partner from the start, for his precious help. Keep in mind the “3M reflex” (Hands-Masks-Meter) to protect yourself… but above all to protect the most vulnerable. Trust and solidarity for this collective fight Dr Guillaume ZAGURY Specialist in International Public Health Consultant in “Health Innovations” ​ HEC In China since 2000. ● “All success is collective”, thanks to: ○ the whole “Back Up” team (Mathieu Bousquet, Carole Gabay, Flavien, Marie, Laetitia, Anne-Sophie, ...), without whom this project would not have been possible. ○ all the “Medical” team (Dr Bachir Athmani, Dr Ibrahim Souare , Dr Taieb, Dr Viateur ...) who allow this project to exist, ○ all historical financial sponsors (Jerome, Benjamin Denis & B Square, Benoit Rossignol, Arnault Bricout) who work for “Citizen Actions” ● If you feel like a patron or of partners to finance IT development, don't hesitate to contact me (guillaume@covidminute.com). ● Also, even if part of the team is based in Shanghai, do not hesitate to come and join us, because there is no shortage of work :-)